Aarti pharma labs Limited has provided clarification to BSE regarding a delay in regulatory disclosure under SEBI regulations. The company submitted the explanation on February 13, 2026, addressing concerns about missing the mandatory 24-hour disclosure timeline.

Disclosure Delay Details

The pharmaceutical company's clarification pertains to a Corporate Announcement that was submitted on February 6, 2026, at 04:21:06 PM under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The regulation mandates that material events be disclosed to stock exchanges within 24 hours of occurrence.

Reason for Delay

According to the company's explanation, the delay occurred due to operational circumstances beyond immediate control. The email communication containing the relevant query was received by the concerned official who was on leave from February 3 to February 5, 2026. This absence resulted in the matter not being addressed within the stipulated regulatory timeline.

The company emphasized that the delay was inadvertent and occurred only because the responsible official was unavailable during the critical period when the disclosure requirement arose.

Company Response

Aarti Pharmalabs Limited has formally requested BSE to take the clarification on record, acknowledging the circumstances that led to the delayed disclosure. The clarification letter was signed by Jeevan Bhargav Mondkar, Company Secretary and Legal Head, who holds ICSI membership number A22565.

The company's proactive approach in providing detailed explanation demonstrates its commitment to regulatory compliance and transparency with stock exchange authorities, despite the inadvertent delay in meeting the disclosure timeline.

Aarti Pharmalabs Limited has announced its financial results for Q3FY26, demonstrating mixed performance across its business segments. The pharmaceutical company, part of the diversified Aarti group with a turnover exceeding INR 130 billion, continues to navigate operational challenges while pursuing strategic expansion initiatives.

Q3FY26 Financial Performance

The company's standalone quarterly results showed operational revenue of INR 4,253 million, representing a marginal increase of 1.9% quarter-on-quarter but a decline of 9.7% year-on-year. EBITDA for the quarter stood at INR 1,030 million with a margin of 24.22%, showing significant improvement from the previous quarter's 17.76%.

Nine-Month Performance Overview

For the nine-month period ending December 2025, the company reported operational revenue of INR 12,179 million, down 1.9% compared to INR 12,417 million in the corresponding period of the previous year. EBITDA for 9M-FY26 was INR 2,720 million with a margin of 22.33%, compared to INR 2,833 million and 22.82% margin in 9M-FY25.

Business Segment Updates

The company operates across three main segments: Xanthine derivatives, API & Intermediates, and CDMO/CMO services. The Xanthine expansion project is progressing as planned with mechanical completion expected by March 2026. The expansion will increase total capacity from 5,000 MTPA to over 9,000 MTPA, with the company targeting to increase its global market share from the current 15-20% to 20-25%.

In the CDMO/CMO business, goods worth INR 49 crore were in transit as of December 31, 2025, and could not be booked in Q3FY26 revenue due to accounting standards. The company is working with 21 customers on 59 active projects, of which 40 are in the commercial stage and 19 are under different stages of development.

Operational Challenges and Outlook

The API business continues to face margin pressure despite early signs of recovery. The company plans debottlenecking of the steroid block in its API production facility to create additional capacity. However, Atali Phase 1 is experiencing operational challenges that are impacting production ramp-up, with resolution expected by the end of Q4FY26.

Earnings Call Recording Available

Following the announcement of Q3FY26 results, Aarti Pharmalabs has uploaded the audio recording of its earnings conference call on the company website under Regulation 30 compliance. The recording provides detailed insights into the company's performance and management commentary on business developments. Investors and analysts can access the recording at the company's dedicated Q3FY26 results page.

The company maintains its position as the largest Indian manufacturer of Xanthine derivatives and continues to benefit from the "China+1" shift with its non-Chinese dependent and fully backward integrated manufacturing capabilities. With USFDA approved facilities and regulatory approvals from multiple agencies including EU GMP, EDQM, KFDA, and COFEPRIS, the company is well-positioned in regulated markets.